MGLL and multiple sclerosis: Monoacylglycerol lipase inhibition has been shown to reduce neuropathic pain, chemotherapy‐induced neuropathic pain (Curry et al., 2018), pain induced by models of multiple sclerosis (Brindisi et al., 2016), pain arising from inflammatory states (Burston et al., 2016), joint pain in osteoarthritis models (Philpott & McDougall, 2020), and chronic stress‐induced hyperalgesia (Lomazzo et al., 2015).